Beaufort Securities restated their speculative buy rating on shares of Tiziana Life Sciences PLC (LON:TILS) in a research note released on Thursday morning.

Shares of Tiziana Life Sciences PLC (LON:TILS) traded down 3.588% during mid-day trading on Thursday, hitting GBX 204.875. The company’s stock had a trading volume of 12,492 shares. The company has a 50-day moving average price of GBX 188.86 and a 200-day moving average price of GBX 171.98. Tiziana Life Sciences PLC has a 1-year low of GBX 91.35 and a 1-year high of GBX 232.96. The stock’s market cap is GBX 190.09 million.

About Tiziana Life Sciences PLC

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. The Company is engaged in the research and development of biotechnological and pharmaceutical products. Its subsidiary, Tiziana Pharma Limited (TPL), is formed as a vehicle to acquire and exploit certain intellectual property in biotechnology, specifically a program focused on metastatic breast cancer.

Receive News & Stock Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related stocks with our FREE daily email newsletter.